TGR5 Promotes Cholangiocarcinoma by Interacting with Mortalin
Overview
Authors
Affiliations
Takeda-G-protein-receptor-5 (TGR5) is a G-protein-coupled receptor (GPCR) activated by bile acids, and mortalin is a multipotent chaperone of the HSP70 family. In the present study, TGR5 was detected by immunohistochemistry (IHC) in extrahepatic cholangiocarcinoma (ECC) specimens, and TGR5 expression in ECC tissues and adjacent tissues was compared. In vitro TGR5 was overexpressed and knocked down in human intrahepatic cholangiocarcinoma (ICC) cell line RBE and human extrahepatic cholangiocarcinoma (ECC) cell line QBC-939 to observe its effects on the biological behavior of cholangiocarcinoma (CC) cells, including proliferation, apoptosis and migration. In vivo xenograft model was constructed to explore the role of TGR5 in CC growth. Proteins that interacted with TGR5 were screened using an immunoprecipitation spectrometry approach, and the identified protein was down-regulated to investigate its contribution to CC growth. The present study demonstrated that TGR5 is highly expressed in CC tissues, and strong TGR5 expression may indicate high malignancy in CC. Furthermore, TGR5 promotes CC cell proliferation, migration, and apoptosis resistance. TGR5 boosts CC growth in vivo. In addition, TGR5 combines with mortalin and regulates mortalin expression in the CC cell line. Mortalin participates in the TGR5-induced increase in CC cell proliferation. In conclusion, TGR5 is of clinical significance based on its implications for the degree of malignancy in patients with CC. Mortalin may be a downstream component regulated by TGR5, and TGR5 promotes cholangiocarcinoma at least partially by interacting with mortalin and upregulating its expression. Both TGR5 and mortalin are positive regulators, and may serve as potential therapeutic targets for CC.
Zhang X, Fan Y, Tan K Cell Death Dis. 2024; 15(9):667.
PMID: 39261452 PMC: 11390889. DOI: 10.1038/s41419-024-07049-y.
Cai J, Zhao J, Gao P, Xia Y Transl Androl Urol. 2022; 11(11):1555-1567.
PMID: 36507482 PMC: 9732702. DOI: 10.21037/tau-22-667.
Lei Y, Li G, Li J, Gao S, Lei M, Gong G Discov Oncol. 2022; 13(1):46.
PMID: 35689739 PMC: 9188013. DOI: 10.1007/s12672-022-00504-2.
Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.
Bertolini A, Fiorotto R, Strazzabosco M Semin Immunopathol. 2022; 44(4):547-564.
PMID: 35415765 PMC: 9256560. DOI: 10.1007/s00281-022-00935-7.
Zhao L, Zhang H, Liu X, Xue S, Chen D, Zou J Acta Pharm Sin B. 2022; 12(2):787-800.
PMID: 35256947 PMC: 8897042. DOI: 10.1016/j.apsb.2021.07.011.